The Prostate Cancer Research Institute (PCRI) recently published details of four (4) clinical trials which are recruiting low-risk prostate cancer patients or those currently under active surveillance. Low-risk determination is based upon PSA, Gleason score, and clinical stage. The treatments offered are referred to as “focal therapy” wherein a portion of the prostate is being treated instead of the entire gland. The clinical trials include brachytherapy (radioactive seeds), laser (interstitial thermal therapy) and high intensity focused ultrasound (HIFU). Details concerning location, eligibility criteria, and contact information are provided in the PCRI link. Clinical trial locations include Memorial Sloan Kettering in New York, University of Chicago, Mayo Clinic, City of Hope, and Desert Medical Imaging (California). Three of these studies involve MRI-guided therapies.